TrialEmerging microbes & infections2022

Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial.

Xuan-Yi Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.